Across TCGA pan-cancer cohorts, TSTD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TSTD1 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TSTD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TSTD1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where TSTD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.969	0.776	.003	40	view →
GBM	OS	Median	All	0.224	0.571	.002	24	view →
PDAC	OS	Tertile	All	0.813	0.478	.002	20	view →
HNSC	OS	Quartile	IV	0.526	0.871	.006	15	view →
LUAD	OS	Median	All	0.966	0.794	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TSTD1 tumor-vs-normal RNA expression · all TSTD1 data types